Forum Markets (FRMM)
Market Price (6/23/2026): $4.92 | Market Cap: $104.8 MilSector: Information Technology | Industry: Application Software
Forum Markets (FRMM)
Market Price (6/23/2026): $4.92Market Cap: $104.8 MilSector: Information TechnologyIndustry: Application Software
Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.
Cash is significant % of market capNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -35% Megatrend and thematic driversMegatrends include Markets & Betting. Themes include Prediction Markets. | Weak multi-year price returns2Y Excs Rtn is -104%, 3Y Excs Rtn is -169% Meaningful short interestShort Interest Days-to-CoverDTC = (Short Interest Share Quantity) / (Average Daily Trading Volume). Reflects how many days it would take to cover (close out) the short interest based on average volumes. High DTC can signify an increased risk of a short squeeze. is 10.85, Short Interest % of Basic SharesShort Interest % of Basic Shares = (Short Interest Quantity) / (Basic Shares Outstanding). A high fraction of short interest can indicate potential risk of a short squeeze. is 16% | Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -247 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -2623% Significant share based compensationSBC/Rev LTMShare Based Compensation / Revenue (Sales), Last Twelve Months (LTM) is 2264% Not cash flow generativeCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is -485%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -664% Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -481% High stock price volatilityVol 12M is 281% Key risksFRMM key risks include [1] potential failure of its clinical-stage drug candidates, Show more. |
| Cash is significant % of market capNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -35% |
| Megatrend and thematic driversMegatrends include Markets & Betting. Themes include Prediction Markets. |
| Weak multi-year price returns2Y Excs Rtn is -104%, 3Y Excs Rtn is -169% |
| Meaningful short interestShort Interest Days-to-CoverDTC = (Short Interest Share Quantity) / (Average Daily Trading Volume). Reflects how many days it would take to cover (close out) the short interest based on average volumes. High DTC can signify an increased risk of a short squeeze. is 10.85, Short Interest % of Basic SharesShort Interest % of Basic Shares = (Short Interest Quantity) / (Basic Shares Outstanding). A high fraction of short interest can indicate potential risk of a short squeeze. is 16% |
| Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -247 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -2623% |
| Significant share based compensationSBC/Rev LTMShare Based Compensation / Revenue (Sales), Last Twelve Months (LTM) is 2264% |
| Not cash flow generativeCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is -485%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -664% |
| Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -481% |
| High stock price volatilityVol 12M is 281% |
| Key risksFRMM key risks include [1] potential failure of its clinical-stage drug candidates, Show more. |
Qualitative Assessment
AI Analysis | Feedback
Forum Markets (FRMM) stock has gained about 45% since 2/28/2026 because of the following key factors:
1. Significant Share Repurchase Program Boosted Shareholder Value.
Forum Markets executed a substantial share repurchase program between mid-April and April 28, 2026. The company repurchased and retired approximately 5.8 million shares, representing 28% of its outstanding shares, for an aggregate cost of about $24.9 million, funded by existing cash on its balance sheet. This significant reduction in the share count likely contributed to increased investor confidence and a higher share price.
2. Positive Market Reaction to Fiscal Q1 2026 Earnings and Strategic Outlook.
Despite reporting a net loss of $77.5 million from continuing operations for fiscal Q1 2026 (ended March 31, 2026), the market reacted favorably to the earnings release on May 14, 2026. This positive sentiment was driven by the company's updated 2026 outlook, which projected revenue of $18–$22 million and year-end Assets Under Management (AUM) of $100–$175 million, as well as a narrower-than-expected loss that signaled effective expense management.
Show more
Forum Markets (FRMM) stock has gained about 45% since 2/28/2026 because of the following key factors:
1. Significant Share Repurchase Program Boosted Shareholder Value.
Forum Markets executed a substantial share repurchase program between mid-April and April 28, 2026. The company repurchased and retired approximately 5.8 million shares, representing 28% of its outstanding shares, for an aggregate cost of about $24.9 million, funded by existing cash on its balance sheet. This significant reduction in the share count likely contributed to increased investor confidence and a higher share price.
2. Positive Market Reaction to Fiscal Q1 2026 Earnings and Strategic Outlook.
Despite reporting a net loss of $77.5 million from continuing operations for fiscal Q1 2026 (ended March 31, 2026), the market reacted favorably to the earnings release on May 14, 2026. This positive sentiment was driven by the company's updated 2026 outlook, which projected revenue of $18–$22 million and year-end Assets Under Management (AUM) of $100–$175 million, as well as a narrower-than-expected loss that signaled effective expense management.
3. Favorable Analyst Coverage and Upgraded Price Targets.
During the specified period, several Wall Street analysts initiated coverage or reiterated positive ratings, contributing to investor optimism. Benchmark initiated coverage with a "Speculative Buy" rating and a $5.00 price target in April 2026, subsequently raising it to $9.00 in May 2026. Clear Street also initiated coverage with a "Buy" rating and an $11.00 price target. This increased analyst attention and higher price targets signaled potential upside to investors.
4. Strategic Expansion into AI Infrastructure Bridge Financing.
Forum Markets introduced a new origination vertical focused on AI chip infrastructure bridge financing, specifically for NVIDIA GPU acquisitions. This strategic move into the high-demand artificial intelligence sector, with a target of mid-teens annualized returns over a 60- to 120-day duration, likely excited investors about the company's growth prospects and diversified revenue streams.
5. Significant Insider Buying Activity.
A notable insider transaction occurred on April 28, 2026, when Konstantin Lomashuk, a 10% owner of Forum Markets, purchased warrants to acquire shares totaling $15.2 million. This substantial insider investment indicated strong confidence in the company's future performance and value proposition.
Show less
Stock Movement Drivers
Fundamental Drivers
The 46.2% change in FRMM stock from 2/28/2026 to 6/22/2026 was primarily driven by a 10856.6% change in the company's P/S Multiple.| (LTM values as of) | 2282026 | 6222026 | Change |
|---|---|---|---|
| Stock Price ($) | 3.53 | 5.16 | 46.2% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 4 | 9 | 128.8% |
| P/S Multiple | 0.1 | 11.7 | 10856.6% |
| Shares Outstanding (Mil) | 0 | 21 | -99.4% |
| Cumulative Contribution | 46.2% |
Market Drivers
2/28/2026 to 6/22/2026| Return | Correlation | |
|---|---|---|
| FRMM | 46.2% | |
| Market (SPY) | 8.8% | 22.4% |
| Sector (XLK) | 38.6% | 13.2% |
Fundamental Drivers
The -51.7% change in FRMM stock from 11/30/2025 to 6/22/2026 was primarily driven by a -99.4% change in the company's Shares Outstanding (Mil).| (LTM values as of) | 11302025 | 6222026 | Change |
|---|---|---|---|
| Stock Price ($) | 10.68 | 5.16 | -51.7% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 4 | 9 | 128.8% |
| P/S Multiple | 0.3 | 11.7 | 3521.4% |
| Shares Outstanding (Mil) | 0 | 21 | -99.4% |
| Cumulative Contribution | -51.7% |
Market Drivers
11/30/2025 to 6/22/2026| Return | Correlation | |
|---|---|---|
| FRMM | -51.7% | |
| Market (SPY) | 9.5% | 24.5% |
| Sector (XLK) | 34.6% | 21.8% |
Fundamental Drivers
The -49.7% change in FRMM stock from 5/31/2025 to 6/22/2026 was primarily driven by a null change in the company's P/S Multiple.| (LTM values as of) | 5312025 | 6222026 | Change |
|---|---|---|---|
| Stock Price ($) | 10.25 | 5.16 | -49.7% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 0 | 9 | 9.2233720368547763E17% |
| P/S Multiple | ∞ | 11.7 | |
| Shares Outstanding (Mil) | 0 | 21 | -98.3% |
| Cumulative Contribution | 0.0% |
Market Drivers
5/31/2025 to 6/22/2026| Return | Correlation | |
|---|---|---|
| FRMM | -49.7% | |
| Market (SPY) | 27.7% | 18.4% |
| Sector (XLK) | 67.4% | 16.6% |
Fundamental Drivers
The -97.6% change in FRMM stock from 5/31/2023 to 6/22/2026 was primarily driven by a null change in the company's P/S Multiple.| (LTM values as of) | 5312023 | 6222026 | Change |
|---|---|---|---|
| Stock Price ($) | 216.60 | 5.16 | -97.6% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 0 | 9 | 9.2233720368547763E17% |
| P/S Multiple | ∞ | 11.7 | |
| Shares Outstanding (Mil) | 0 | 21 | -99.9% |
| Cumulative Contribution | 0.0% |
Market Drivers
5/31/2023 to 6/22/2026| Return | Correlation | |
|---|---|---|
| FRMM | -97.6% | |
| Market (SPY) | 85.1% | 9.6% |
| Sector (XLK) | 138.8% | 7.8% |
Price Returns Compared
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | Total [1] | |
|---|---|---|---|---|---|---|---|
| Returns | |||||||
| FRMM Return | 43% | -96% | -94% | -55% | -73% | 3% | -100% |
| Peers Return | -8% | -34% | -15% | 89% | -46% | -1% | -47% |
| S&P 500 Return | 27% | -19% | 24% | 23% | 16% | 10% | 100% |
Monthly Win Rates [3] | |||||||
| FRMM Win Rate | 50% | 17% | 8% | 33% | 17% | 33% | |
| Peers Win Rate | 50% | 25% | 52% | 78% | 53% | 47% | |
| S&P 500 Win Rate | 75% | 42% | 67% | 75% | 67% | 50% | |
Max Drawdowns [4] | |||||||
| FRMM Max Drawdown | -73% | -98% | -97% | -79% | -95% | -68% | |
| Peers Max Drawdown | -27% | -42% | -17% | -55% | -62% | -43% | |
| S&P 500 Max Drawdown | -5% | -25% | -10% | -8% | -19% | -9% | |
[1] Cumulative total returns since the beginning of 2021
[2] Peers: ADSK, HIT, BMR, QNT, RTB.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2026 data is for the year up to 6/22/2026 (YTD)
How Low Can It Go
| Event | FRMM | S&P 500 |
|---|---|---|
| 2025 US Tariff Shock | ||
| % Loss | -46.0% | -18.8% |
| % Gain to Breakeven | 85.2% | 23.1% |
| Time to Breakeven | 21 days | 79 days |
| 2024 Yen Carry Trade Unwind | ||
| % Loss | -27.7% | -7.8% |
| % Gain to Breakeven | 38.2% | 8.5% |
| Time to Breakeven | 23 days | 18 days |
In The Past
Forum Markets's stock fell -46.0% during the 2025 US Tariff Shock. Such a loss loss requires a 85.2% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
| Event | FRMM | S&P 500 |
|---|---|---|
| 2025 US Tariff Shock | ||
| % Loss | -46.0% | -18.8% |
| % Gain to Breakeven | 85.2% | 23.1% |
| Time to Breakeven | 21 days | 79 days |
| 2024 Yen Carry Trade Unwind | ||
| % Loss | -27.7% | -7.8% |
| % Gain to Breakeven | 38.2% | 8.5% |
| Time to Breakeven | 23 days | 18 days |
In The Past
Forum Markets's stock fell -46.0% during the 2025 US Tariff Shock. Such a loss loss requires a 85.2% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
About Forum Markets (FRMM)
Forum Markets (FRMM), operating as 1180 Life Sciences Corp., is a clinical-stage biotechnology company focused on developing novel therapeutic treatments. The company's core mission is to address significant unmet medical needs in challenging areas such as chronic pain, inflammation, fibrosis, and other related inflammatory diseases through advanced drug development.
FRMM's product pipeline is structured around three distinct development platforms. The most advanced is the Fibrosis and anti-TNF platform, which is currently in Phase IIb clinical trials, targeting both fibrosis and anti-tumor necrosis factor. In addition, the company is advancing two preclinical-stage platforms: the Synthetic Cannabidiol (CBD) Analogs platform, which focuses on creating man-made derivatives of CBD, and the a7nAChR platform, designed to develop immune suppressive treatments by targeting the alpha 7 nicotinic acetylcholine receptor.
Forum Markets primarily serves the global medical market, with a focus on patients suffering from chronic pain, a variety of inflammatory conditions, and fibrotic diseases. Its ultimate customers are healthcare providers and patients who require innovative and effective treatments for conditions where current therapies are often inadequate. The company operates within the pharmaceutical and biotechnology industry, aiming to bring prescription drugs to market.
AI Analysis | Feedback
1. It's like a clinical-stage Vertex Pharmaceuticals, but developing drugs for chronic pain and fibrosis instead of cystic fibrosis.
2. Think of it as an early-stage Amgen or Gilead Sciences, building a pipeline of novel therapeutics for inflammatory diseases and pain.
AI Analysis | Feedback
- Fibrosis and Anti-TNF Platform: This platform develops therapeutics for fibrosis and anti-tumor necrosis factor-related inflammatory diseases, currently in Phase IIb clinical trials.
- Synthetic Cannabidiol (CBD) Analogs Platform: This platform focuses on developing man-made derivatives of CBD for various medical needs, currently in preclinical trials.
- a7nAChR Platform: This platform explores the alpha 7 nicotinic acetylcholine receptor for its immune suppressive potential, currently in preclinical trials.
AI Analysis | Feedback
As a clinical-stage biotechnology company, 1180 Life Sciences Corp. (trading under the symbol FRMM) is currently focused on the development of therapeutics through preclinical and clinical trials. At this stage, the company does not have commercialized products available for sale to major customers, whether other companies or individuals. Its primary activities revolve around research, development, and securing financing for its drug candidates.
```AI Analysis | Feedback
AI Analysis | Feedback
McAndrew Rudisill - Chief Executive Officer
McAndrew Rudisill was appointed Chief Executive Officer of Forum Markets, Incorporated (FRMM) in September 2025. He joined the company's Board of Directors in July 2025.
John T. Saunders - Chief Financial Officer
John T. Saunders was promoted to Chief Financial Officer on November 14, 2025. He assumed this role after Omar Jimenez resigned as CFO in December 2024, at which point Blair Jordan, the Interim CEO, also served as interim principal financial and accounting officer.
Quan A. Vu - Chief Operating Officer & Chief Business Officer
Mr. Vu is a highly experienced strategy, corporate/business development, finance, and operations executive with 20 years of biopharma experience. Prior to joining 180 Life Sciences, Mr. Vu served as a CBO/CFO consultant for LS Associates and as a Managing Director and Co-Head of Healthcare IT at Solganick & Co., a technology investment bank providing M&A advisory. He also served as CEO of Baleena Bioscience, a company focused on consolidating biotechnology/medical device assets with the aim of going public.
Robert Spake - General Counsel
Robert Spake was appointed as General Counsel of Forum Markets, Incorporated on March 3, 2026.
Blair Jordan - Former Interim Chief Executive Officer & Interim Principal Financial and Accounting Officer
Blair Jordan served as the Interim Chief Executive Officer of 180 Life Sciences Corp. and, following the resignation of Omar Jimenez, took on the additional interim role of principal financial and accounting officer in December 2024. He was appointed CEO on February 4, 2025. During his tenure as Interim CEO, Jordan was instrumental in the company's strategic pivot into the online gaming industry.
AI Analysis | Feedback
- Clinical Trial Failure and Regulatory Approval Risk: As a clinical-stage biotechnology company, 1180 Life Sciences Corp.'s success is critically dependent on the successful progression of its therapeutic candidates through rigorous and lengthy clinical trials and subsequent regulatory approvals. The company has products under Phase IIb and preclinical trials. Drug development is associated with high costs, extended timelines, and a high attrition rate, with less than 12% of candidate drugs making it to market. Any setbacks at various stages, such as unexpected adverse events, lack of demonstrated efficacy, difficulties in patient recruitment, regulatory delays, or outright rejection, could lead to substantial financial losses and missed opportunities.
- Funding Challenges and Financial Distress: The development of new therapeutics is an extremely capital-intensive endeavor. Forum Markets (FRMM) faces significant financial risks, as indicated by a high Probability of Financial Distress of 77.29% as of September 2025 and a GuruFocus GF Score of 31/100, reflecting poor overall financial health. The company has also reported a stockholders' deficit and did not meet the minimum stockholders' equity required for continued listing on Nasdaq, raising concerns about potential delisting. A tightening capital market and cautious investor sentiment further exacerbate the challenges for early-stage biotechnology companies to secure necessary funding.
- Intellectual Property (IP) Challenges: The protection of its product development platforms, including fibrosis and anti-TNF, Synthetic Cannabidiol (CBD) Analogs, and a7nAChR platforms, is fundamental to 1180 Life Sciences Corp.'s business. Intellectual property provides the legal framework for new discoveries and a competitive advantage. Challenges related to securing, maintaining, and defending its intellectual property can significantly impede the company's ability to commercialize its products. Furthermore, the expiration of patents (patent cliff) and potential challenges from generic competitors pose ongoing threats to the long-term revenue streams of biotechnology firms.
AI Analysis | Feedback
AI Analysis | Feedback
AI Analysis | Feedback
AI Analysis | Feedback
Research & Analysis
Invest in Strategies
Wealth Management
Peer Comparisons
| Peers to compare with: |
Financials
| Median | |
|---|---|
| Name | |
| Mkt Price | 8.81 |
| Mkt Cap | 0.1 |
| Rev LTM | 34 |
| Op Inc LTM | -1 |
| FCF LTM | -4 |
| FCF 3Y Avg | -1 |
| CFO LTM | -1 |
| CFO 3Y Avg | 1 |
Growth & Margins
| Median | |
|---|---|
| Name | |
| Rev Chg LTM | 35.3% |
| Rev Chg 3Y Avg | 13.8% |
| Rev Chg Q | 13.9% |
| QoQ Delta Rev Chg LTM | 4.2% |
| Op Inc Chg LTM | -197.6% |
| Op Inc Chg 3Y Avg | -721.5% |
| Op Mgn LTM | -3.3% |
| Op Mgn 3Y Avg | 14.3% |
| QoQ Delta Op Mgn LTM | 2.1% |
| CFO/Rev LTM | -2.1% |
| CFO/Rev 3Y Avg | 16.2% |
| FCF/Rev LTM | -10.4% |
| FCF/Rev 3Y Avg | 12.4% |
Price Behavior
| Market Price | $5.16 | |
| Market Cap ($ Bil) | 0.1 | |
| First Trading Date | 06/27/2017 | |
| Distance from 52W High | -95.2% | |
| 50 Days | 200 Days | |
| DMA Price | $4.50 | $9.18 |
| DMA Trend | down | up |
| Distance from DMA | 14.6% | -43.8% |
| 3M | 1YR | |
| Volatility | 201.0% | 281.7% |
| Downside Capture | 239.89 | 497.36 |
| Upside Capture | 334.75 | 308.66 |
| Correlation (SPY) | 19.0% | 18.7% |
| 1M | 2M | 3M | 6M | 1Y | 3Y | |
|---|---|---|---|---|---|---|
| Beta | 3.95 | 6.23 | 4.20 | 3.91 | 4.85 | 1.81 |
| Up Beta | -6.19 | 5.00 | 3.46 | 4.44 | 5.26 | 0.61 |
| Down Beta | 17.88 | 10.62 | 3.57 | 3.16 | 2.82 | 0.56 |
| Up Capture | 80% | 602% | 582% | 257% | 912% | 392% |
| Bmk +ve Days | 13 | 28 | 36 | 67 | 141 | 432 |
| Stock +ve Days | 9 | 20 | 30 | 55 | 104 | 301 |
| Down Capture | 873% | 749% | 353% | 300% | 219% | 114% |
| Bmk -ve Days | 7 | 13 | 27 | 57 | 109 | 318 |
| Stock -ve Days | 11 | 20 | 30 | 66 | 141 | 419 |
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
Based On 1-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with FRMM | |
|---|---|---|---|---|
| FRMM | -41.5% | 280.6% | 0.65 | - |
| Sector ETF (XLK) | 60.3% | 23.1% | 1.97 | 16.8% |
| Equity (SPY) | 26.1% | 12.4% | 1.59 | 18.6% |
| Gold (GLD) | 24.1% | 27.5% | 0.77 | 2.9% |
| Commodities (DBC) | 18.5% | 18.8% | 0.77 | -6.4% |
| Real Estate (VNQ) | 11.8% | 13.8% | 0.57 | 8.2% |
| Bitcoin (BTCUSD) | -40.2% | 42.5% | -1.09 | 19.5% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 5-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with FRMM | |
|---|---|---|---|---|
| FRMM | -83.2% | 230.5% | -0.10 | - |
| Sector ETF (XLK) | 22.7% | 25.3% | 0.79 | 9.4% |
| Equity (SPY) | 13.4% | 17.1% | 0.61 | 10.2% |
| Gold (GLD) | 17.1% | 18.3% | 0.76 | 2.7% |
| Commodities (DBC) | 7.5% | 19.4% | 0.28 | -1.1% |
| Real Estate (VNQ) | 2.1% | 18.9% | 0.01 | 8.3% |
| Bitcoin (BTCUSD) | 9.4% | 54.1% | 0.37 | 9.1% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 10-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with FRMM | |
|---|---|---|---|---|
| FRMM | -58.8% | 176.9% | -0.03 | - |
| Sector ETF (XLK) | 25.6% | 24.7% | 0.93 | 7.8% |
| Equity (SPY) | 15.4% | 18.0% | 0.73 | 7.7% |
| Gold (GLD) | 12.2% | 16.1% | 0.62 | 3.1% |
| Commodities (DBC) | 6.0% | 18.0% | 0.26 | 0.0% |
| Real Estate (VNQ) | 5.4% | 20.7% | 0.23 | 6.0% |
| Bitcoin (BTCUSD) | 59.9% | 66.8% | 1.00 | 5.5% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Earnings Returns History
Updated 6/17/2026| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| 5/14/2026 | 9.2% | -7.0% | 20.0% |
| 11/14/2025 | -8.2% | -35.9% | -57.7% |
| SUMMARY STATS | |||
| # Positive | 1 | 0 | 1 |
| # Negative | 1 | 2 | 1 |
| Median Positive | 9.2% | 20.0% | |
| Median Negative | -8.2% | -21.4% | -57.7% |
| Max Positive | 9.2% | 20.0% | |
| Max Negative | -8.2% | -35.9% | -57.7% |
| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| 5/14/2026 | 9.2% | -7.0% | 20.0% |
| 11/14/2025 | -8.2% | -35.9% | -57.7% |
| SUMMARY STATS | |||
| # Positive | 1 | 0 | 1 |
| # Negative | 1 | 2 | 1 |
| Median Positive | 9.2% | 20.0% | |
| Median Negative | -8.2% | -21.4% | -57.7% |
| Max Positive | 9.2% | 20.0% | |
| Max Negative | -8.2% | -35.9% | -57.7% |
SEC Filings
Expand for More| Report Date | Filing Date | Filing |
|---|---|---|
| 03/31/2026 | 05/15/2026 | 10-Q |
| 12/31/2025 | 04/01/2026 | 10-K |
| 09/30/2025 | 11/14/2025 | 10-Q |
| 06/30/2025 | 07/23/2025 | 10-Q |
| 03/31/2025 | 05/15/2025 | 10-Q |
| 12/31/2024 | 03/31/2025 | 10-K |
| 09/30/2024 | 11/14/2024 | 10-Q |
| 06/30/2024 | 08/12/2024 | 10-Q |
| 03/31/2024 | 05/15/2024 | 10-Q |
| 12/31/2023 | 03/25/2024 | 10-K |
| 09/30/2023 | 11/09/2023 | 10-Q |
| 06/30/2023 | 08/15/2023 | 10-Q |
| 03/31/2023 | 05/15/2023 | 10-Q |
| 12/31/2022 | 03/31/2023 | 10-K |
| 09/30/2022 | 11/10/2022 | 10-Q |
| 06/30/2022 | 08/09/2022 | 10-Q |
| Report Date | Filing Date | Filing |
|---|---|---|
| 03/31/2026 | 05/15/2026 | 10-Q |
| 12/31/2025 | 04/01/2026 | 10-K |
| 09/30/2025 | 11/14/2025 | 10-Q |
| 06/30/2025 | 07/23/2025 | 10-Q |
| 03/31/2025 | 05/15/2025 | 10-Q |
| 12/31/2024 | 03/31/2025 | 10-K |
| 09/30/2024 | 11/14/2024 | 10-Q |
| 06/30/2024 | 08/12/2024 | 10-Q |
| 03/31/2024 | 05/15/2024 | 10-Q |
| 12/31/2023 | 03/25/2024 | 10-K |
| 09/30/2023 | 11/09/2023 | 10-Q |
| 06/30/2023 | 08/15/2023 | 10-Q |
| 03/31/2023 | 05/15/2023 | 10-Q |
| 12/31/2022 | 03/31/2023 | 10-K |
| 09/30/2022 | 11/10/2022 | 10-Q |
| 06/30/2022 | 08/09/2022 | 10-Q |
| 03/31/2022 | 05/16/2022 | 10-Q |
| 12/31/2021 | 03/31/2022 | 10-K |
| 09/30/2021 | 11/15/2021 | 10-Q |
| 06/30/2021 | 08/16/2021 | 10-Q |
| 03/31/2021 | 07/19/2021 | 10-Q |
| 12/31/2020 | 07/09/2021 | 10-K |
| 09/30/2019 | 02/05/2021 | 10-Q/A |
| 06/30/2019 | 02/05/2021 | 10-Q/A |
Recent Forward Guidance
Updated 6/1/2026Latest: Q1 2026 Earnings Reported 5/14/2026
| Forward Guidance | Guidance Change | ||||||
|---|---|---|---|---|---|---|---|
| Metric | Low | Mid | High | % Chg | % Delta | Change | Prior |
| 2026 Assets Under Management (AUM) | 100.00 Mil | 137.50 Mil | 175.00 Mil | Higher New | |||
| 2026 Revenue | 18.00 Mil | 20.00 Mil | 22.00 Mil | Higher New | |||
| 2027 Assets Under Management (AUM) | 250.00 Mil | 275.00 Mil | 300.00 Mil | Higher New | |||
| 2027 Revenue Growth | 50.0% | 75.0% | 100.0% | Higher New | |||
Industry Resources
| Information Technology Resources |
| TechCrunch |
| Wired |
| CIO |
| MIT Technology Review |
| Gartner Insights |
| Ars Technica |
| Application Software Resources |
| Capterra |
| Software Advice |
| InfoWorld |
External Quote Links
| Y Finance | Barrons |
| TradingView | Morningstar |
| SeekingAlpha | ValueLine |
| Motley Fool | Robinhood |
| CNBC | Etrade |
| MarketWatch | Unusual Whales |
| YCharts | Perplexity Finance |
| FinViz |
Prefer one of these to Trefis? Tell us why.